A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
Study of Immune Therapy Drugs in Addition to the Usual Radiation Therapy for Patients with Brain Cancer (Glioblastoma)
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAT8904
U.S. Govt. ID: NCT04729959
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to answer the following question: Can we shrink or stabilize your brain cancer by adding immune therapy drugs to the usual radiation therapy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your recurrent glioblastoma. The usual approach is defined as care most people get for recurrent glioblastoma.
Fabio Iwamoto, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with glioblastoma (GBM)? Yes No
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator